Increased levels of adiponectin in non-human primates and humans with metabolic disease (type 2 diabetes, obesity and NASH) have been consistently observed following treatment with various FGF21 analogs (183, 244–246). Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.